Status:
COMPLETED
A New Oral Treatment For Type II Diabetes Mellitus
Lead Sponsor:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.
Detailed Description
A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093, Administered Orally, Once Daily,...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Women must not be pregnant and must not be breastfeeding.
- Have Type II diabetes.
- Not taking any medicine for diabetes, or taking one oral medicine for their diabetes.
- Exclusion criteria:
- Have any underlying or significant active disease that would prevent the subject from safely participating in the trial by the judgement of the study doctor.
Exclusion
Key Trial Info
Start Date :
April 28 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 21 2006
Estimated Enrollment :
375 Patients enrolled
Trial Details
Trial ID
NCT00111800
Start Date
April 28 2005
End Date
July 21 2006
Last Update
March 21 2018
Active Locations (109)
Enter a location and click search to find clinical trials sorted by distance.
1
GSK Investigational Site
Long Beach, California, United States, 90806
2
GSK Investigational Site
Pasadena, California, United States, 91105
3
GSK Investigational Site
Denver, Colorado, United States, 80220
4
GSK Investigational Site
Hollywood, Florida, United States, 33021